Summary
Drug Discovery in modern times straddles three main periods. The first notable period can be traced to the nineteenth century where the basis of drug discovery relied on the serendipity of the medicinal chemists. The second period commenced around the early twentieth century when new drug structures were found, which contributed for a new era of antibiotics discovery. Based on these known structures, and with the development of powerful new techniques such as molecular modelling, combinatorial chemistry, and automated high-throughput screening, rapid advances occurred in drug discovery towards the end of the century. The period also was revolutionized by the emergence of recombinant DNA technology, where it became possible to develop potential drugs target candidates. With all the expansion of new technologies and the onset of the “Omics” revolution in the twenty-first century, the third period has kick-started with an increase in biopharmaceutical drugs approved by FDA/EMEA for therapeutic use.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Drews, J. (2000). Drug discovery: a historical perspective. Science 287, 1960–1964
Thomas, G. (2000). Medicinal Chemistry – An Introduction. Wiley, England
Chin, Y., Balunas, M.J., Chai, H.B., and Kinghorn, A.D. (2006). Drug discovery from natural sources.AAPS J 2, E239–E253
Zhang, M. and Wilkinson, B. (2007). Drug discovery beyond the “rule-of-five”. Curr Opin Biotechnol 18, 478–488
Lombardino, J.G. and Lowe, J.A. III. (2004). The role of the medicinal chemist in drug discovery – then and now. Nat Rev Drug Discov 3, 853–862
Niwayama, S. (2006). Proteomics in medicinal chemistry. Mini Rev Med Chem 6, 241–246
Sleno, L. and Emili, A. (2008). Proteomic methods for drug target discovery. Curr Opin Chem Biol 12, 1–9
Ahn, N.G. and Wang, A.H.-J. (2008). Proteomics and genomics: perspectives on drug and target discovery. Curr Opin Chem Biol 12, 1–3
Veenstra, T.D. (2006). Proteomic approaches in the drug discovery. Drug Discov Today Tech 3, 193–195
Kopec, K.K., Bozyczko-Coyne, D., and Williams, M. (2005). Target identification and validation in drug discovery: the role of proteomics. Biochem Pharmacol 69, 1133–1139
Katayama, H. and Oda, Y. (2007). Chemical proteomics for drug discovery based on compound-immobilized affinity chromatography. J Chromatogr B 855, 21–27
Gershell, L.J. and Atkins, J.H. (2003). A brief history of novel drug discovery technologies. Nat Rev Drug Discov 2, 321–327
Gupta, P. and Lee, K.H. (2007). Genomics and proteomics in process development: opportunities and challenges. Trends Biotechnol 25, 324–330
Bleicher, K.H., Böhm, H., Müller, K., and Alanine, A.I. (2003). Hit and lead generation: beyond high-throughput screening. Nat Rev Drug Discov 2, 369–378
Kerns, E.H. and Di, L. (2003). Pharmaceutical profiling in drug discovery. Drug Discov Today 8, 316–323
Di, L. and Kerns, E.H. (2003). Profilling drug-like properties in discovery research. Curr Opin Chem Biol 7, 402–408
Yengi, L.G., Leung, L., and Kao, J. (2007). The evolving role of drug metabolism in drug discovery and development. Pharm Res 24, 842–858
Lipinski, C.A., Lombardo, F., Dominy, B.W., and Feeney, P.J. (2001). Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 46, 3–26
Han, S. and Kim, S.H. (2007). Introduction to chemical proteomics for drug discovery and development. Arch Pharm 340, 169–177
Ryan, T.E. and Patterson, S.D. (2002). Proteomics in drug target discovery – high-throughput meets high-efficiency. Drug Discov World 3, 43–52
Edwards, A.M., Arrowsnith, C.H., Christendat, D., Dharams, A., Friesen, J.D., Greenblatt, J.F., and Vedadi, M. (2000). Protein production: feeding the crystallographers and NMR spectroscopists. Nat Struct Biol 7, 970–972
Schmid, M.B. (2002). Structural proteomics: the potential of high-throughput structure determination. Trends Microbiol 10, S27–S31
Jain, K. (2002). New routes for drug discovery. Drug Discov Today 7, 900–902
Newman, D.J., Cragg, G.M., and Snader, K.M. (2000). The influence of natural products upon drug discovery. Nat Prod Rep 17, 215–234
Balaram, P. (2004). Drug discovery: myth and reality. Curr Sci 87, 847–848
Triggle, D.J. (2007). Drug discovery and delivery in the 21st century. Med Princ Pract 16, 1–14
Kayser, O. and Müller, R.H. (2004). Pharmaceutical Biotechnology, Drug Discovery and Clinical Applications. Wiley, England
Walsh, G. (2003). Biopharmaceuticals: Biochemistry and Biotechnology. Wiley, England
Dudzinski, D.M. and Kesselheim, S. (2008). Scientific and legal viability of follow-on protein drugs. N Engl J Med 358, 843–848
Hughes, B. (2008). 2007 FDA drug appro-vals: a year of flux. Nat Rev Drug Discov 7, 107–109
Tucker, J., Yakatan, S., and Yakatan, S. (2008). Biogenerics 2007: how far have we come? J Commer Biotechnol 14, 56–64
Lawrence, S. (2007). Billion dollar babies - biotech drugs as blockbusters. Nat Biotechnol 25, 380–382
Sartipy, P., Björquist, P., Strehl, R., and Hyllner, J. (2007). The application of human embryonic stem cell technologies to drug discovery. Drug Discov Today 12, 688–699
Friel, R., van der Sar, S., and Mee, P.J. (2005). Embryonic stem cells: understanding their history, cell biology and signalling. Adv Drug Deliv Rev 57, 1894–1903
Keller, G. (2005). Embryonic stem cell differentiation: emergence of a new era in biology and medicine. Genes Dev 19, 1129–1155
McNeish, J.D. (2007). Stem cells as screening tools in drug discovery. Curr Opin Pharmacol 7, 515–520
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2010 Humana Press
About this protocol
Cite this protocol
Pina, A.S., Hussain, A., Roque, A.C.A. (2010). An Historical Overview of Drug Discovery. In: Roque, A. (eds) Ligand-Macromolecular Interactions in Drug Discovery. Methods in Molecular Biology, vol 572. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-60761-244-5_1
Download citation
DOI: https://doi.org/10.1007/978-1-60761-244-5_1
Published:
Publisher Name: Humana Press, Totowa, NJ
Print ISBN: 978-1-60761-243-8
Online ISBN: 978-1-60761-244-5
eBook Packages: Springer Protocols